In the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial, treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin, added to other guideline-directed medical therapy, reduced the risk of worsening heart failure (HF) events and cardiovascular death in patients with HF with reduced ejection fraction (HFrEF) (hazard ratio [HR], 0.74; 95% CI, 0.65-0.85;
P < .001).
1 With many different therapeutic options available for patients with HFrEF, clinical inertia often underlies deferred initiation of additional beneficial therapy, which ultimately leads to preventable adverse HF events.
2 To frame these potential lost opportunities with respect to dapagliflozin, we examined the timing of onset of clinical benefit with dapagliflozin in the DAPA-HF trial.